These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20535961)

  • 1. [Cancer treatment by comprehensive regulation of anti-tumor immune network].
    Kawakami Y
    Nihon Rinsho; 2010 Jun; 68(6):1094-9. PubMed ID: 20535961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of cancer using dendritic cells.
    Morse MA; Lyerly HK
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):35-44. PubMed ID: 9557215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
    van den Eynde B
    Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells in cancer immunotherapy.
    Gunzer M; Grabbe S
    Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccination for cancer therapy.
    Nestle FO
    Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
    Melief CJ; Kast WM
    Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathological approaches to human tumor immunology.
    Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T
    Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor immunity and immunotherapy.
    Boura P; Kountouras J; Lygidakis NJ
    Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy targeting cancer stem cells].
    Kawakami Y; Matsushita M; Ueda R; Tsukamoto N; Ohta S
    Nihon Rinsho; 2012 Dec; 70(12):2142-6. PubMed ID: 23259387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.